Percent of patients with monthly serum phosphorus ≤ 5.5 mg/dL at baseline and SO follow-up. PB pills/day for patients with in-range serum phosphorus decreased from (9.7, 8.8, and 9.0) at baseline to (3.9, 4.4, 4.2, 4.4, 4.5, and 4.8) at SO follow-up. SO, sucroferric oxyhydroxide; PB, phosphate binder.